CIPROFLOXACIN 250, 500 – EXIR
F.C.tablet Ciprofloxacin 250, 500 mg
| Generic Name of Product | Brand Name | Dosage Form | Strength | Pharmacologic Group | Therapeutic Group | Unit Per Pack |
| Ciprofloxacin | Ciproxir | Tablet, vial | 500mg,200mg/20ml | Fluoroquinolone | Antibacterial agent | 20, 1 |
Indications And Usage | Ciprofloxacin is indicated for the treatment of complicated urinary tract infections and pyelonephritis due to Escherichia coli. | |
Administration | The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative organism, the integrity of the patient’s host-defense mechanisms, and the status of renal function and hepatic function. | |
Contraindications | A history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. A history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin. | |
Precautions |
| |
Adverse Reactions |
interstitial nephritis, nephritis, renal failure, polyuria, urinary retention, urethral bleeding, vaginitis, acidosis, breast pain | |
Pregnancy and lactation | Category C
| |
Renal and liver Impairment | - | |
Laboratory Tests | Changes in laboratory parameters listed as adverse events without regard to drug relationship are listed below: Hepatic – Elevations of ALT (SGPT) (1.9%), AST (SGOT) (1.7%), alkaline phosphatase (0.8%), LDH (0.4%), serum bilirubin (0.3%). Hematologic – Eosinophilia (0.6%), leukopenia (0.4%), decreased blood platelets (0.1%), elevated blood platelets (0.1%), pancytopenia (0.1%). Renal – Elevations of serum creatinine (1.1%), BUN (0.9%), CRYSTALLURIA, CYLINDRURIA, AND HEMATURIA HAVE BEEN REPORTED. |
